The First-in-Class ERK Inhibitor Ulixertinib Shows Promising Activity in MAPK-Driven Pediatric Low-Grade Glioma Models

Scientists investigated the anti-tumoral activity of ulixertinib monotherapy as well as in combination with MEK inhibitors, BH3-mimetics, or chemotherapy in pediatric low-grade gliomas.